{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T14:57:39Z","timestamp":1787065059289,"version":"build-2736575974"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"1-2","license":[{"start":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T00:00:00Z","timestamp":1740009600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T00:00:00Z","timestamp":1740009600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"donations from the Weisman Family, Mr. Michael Burke, and Mr. Michael Shmerling"},{"DOI":"10.13039\/501100001691","name":"MEXT | Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["22K15772"],"award-info":[{"award-number":["22K15772"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["24dk0307121h0001"],"award-info":[{"award-number":["24dk0307121h0001"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharmacogenomics J"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1038\/s41397-024-00360-z","type":"journal-article","created":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T06:32:01Z","timestamp":1740033121000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Genetic markers of early response to lurasidone in acute schizophrenia"],"prefix":"10.1038","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5271-5927","authenticated-orcid":false,"given":"Akane","family":"Yoshikawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7006-1285","authenticated-orcid":false,"given":"Jiang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8594-5676","authenticated-orcid":false,"given":"Ney","family":"Alliey-Rodriguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4901-8845","authenticated-orcid":false,"given":"Herbert Y.","family":"Meltzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,20]]},"reference":[{"key":"360_CR1","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1176\/appi.ajp.2020.177901","volume":"177","author":"GA Keepers","year":"2020","unstructured":"Keepers GA, Fochtmann LJ, Anzia JM, Benjamin S, Lyness JM, Mojtabai R, et al. The American Psychiatric Association practice guideline for the treatment of patients with schizophrenia. Am J Psychiatry. 2020;177:868\u201372.","journal-title":"Am J Psychiatry"},{"key":"360_CR2","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1177\/0269881119889296","volume":"34","author":"TR Barnes","year":"2020","unstructured":"Barnes TR, Drake R, Paton C, Cooper SJ, Deakin B, Ferrier IN, et al. Evidence-based guidelines for the pharmacological treatment of schizophrenia: updated recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2020;34:3\u201378.","journal-title":"J Psychopharmacol."},{"key":"360_CR3","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1001\/jamapsychiatry.2019.3377","volume":"77","author":"CU Correll","year":"2020","unstructured":"Correll CU, Kane JM. Ranking antipsychotics for efficacy and safety in schizophrenia. JAMA Psychiatry. 2020;77:225\u20136.","journal-title":"JAMA Psychiatry"},{"key":"360_CR4","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/S0140-6736(19)31135-3","volume":"394","author":"M Huhn","year":"2019","unstructured":"Huhn M, Nikolakopoulou A, Schneider-Thoma J, Krause M, Samara M, Peter N, et al. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. Lancet. 2019;394:939\u201351.","journal-title":"Lancet"},{"key":"360_CR5","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1124\/jpet.110.167346","volume":"334","author":"T Ishibashi","year":"2010","unstructured":"Ishibashi T, Horisawa T, Tokuda K, Ishiyama T, Ogasa M, Tagashira R, et al. Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7 (5-HT7) and 5-HT1A receptor activity. J Pharmacol Exp Ther. 2010;334:171\u201381.","journal-title":"J Pharmacol Exp Ther"},{"key":"360_CR6","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/S0022-3565(25)20710-8","volume":"251","author":"HY Meltzer","year":"1989","unstructured":"Meltzer HY, Matsubara S, Lee J. Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values. J Pharmacol Exp Ther. 1989;251:238\u201346.","journal-title":"J Pharmacol Exp Ther"},{"key":"360_CR7","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1080\/14656566.2022.2141568","volume":"23","author":"A Fiorillo","year":"2022","unstructured":"Fiorillo A, Cuomo A, Sampogna G, Albert U, Cal\u00f2 P, Cerveri G, et al. Lurasidone in adolescents and adults with schizophrenia: from clinical trials to real-world clinical practice. Expert Opin Pharmacother. 2022;23:1801\u201318.","journal-title":"Expert Opin Pharmacother"},{"key":"360_CR8","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1176\/appi.ajp.2017.16121358","volume":"174","author":"S Leucht","year":"2017","unstructured":"Leucht S, Leucht C, Huhn M, Chaimani A, Mavridis D, Helfer B, et al. Sixty years of placebo-controlled antipsychotic drug trials in acute schizophrenia: systematic review, Bayesian meta-analysis, and meta-regression of efficacy predictors. Am J Psychiatry. 2017;174:927\u201342.","journal-title":"Am J Psychiatry"},{"key":"360_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.schres.2019.04.009","volume":"208","author":"AT Chen","year":"2019","unstructured":"Chen AT, Nasrallah HA. Neuroprotective effects of the second generation antipsychotics. Schizophr Res. 2019;208:1\u20137.","journal-title":"Schizophr Res."},{"key":"360_CR10","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1097\/JCP.0000000000001205","volume":"40","author":"HY Meltzer","year":"2020","unstructured":"Meltzer HY, Share DB, Jayathilake K, Salomon RM, Lee MA. Lurasidone improves psychopathology and cognition in treatment-resistant schizophrenia. J Clin Psychopharmacol. 2020;40:240.","journal-title":"J Clin Psychopharmacol."},{"key":"360_CR11","doi-asserted-by":"publisher","first-page":"193","DOI":"10.2165\/00023210-200923030-00002","volume":"23","author":"P Thomas","year":"2009","unstructured":"Thomas P, Alptekin K, Gheorghe M, Mauri M, Olivares JM, Riedel M. Management of patients presenting with acute psychotic episodes of schizophrenia. CNS Drugs. 2009;23:193\u2013212.","journal-title":"CNS Drugs"},{"key":"360_CR12","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1176\/appi.ajp.2015.14101329","volume":"172","author":"MT Samara","year":"2015","unstructured":"Samara MT, Leucht C, Leeflang MM, Anghelescu I-G, Chung Y-C, Crespo-Facorro B, et al. Early improvement as a predictor of later response to antipsychotics in schizophrenia: a diagnostic test review. Am J Psychiatry. 2015;172:617\u201329.","journal-title":"Am J Psychiatry"},{"key":"360_CR13","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1111\/pcn.13377","volume":"76","author":"T Kishi","year":"2022","unstructured":"Kishi T, Nakamura H, Iwata N. Early improvement as a predictor of later response to lurasidone in schizophrenia from Japan trials: a diagnostic test. Psychiatry Clin Neurosci. 2022;76:401\u20132.","journal-title":"Psychiatry Clin Neurosci."},{"key":"360_CR14","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/S2215-0366(15)00553-2","volume":"3","author":"DM Ruderfer","year":"2016","unstructured":"Ruderfer DM, Charney AW, Readhead B, Kidd BA, K\u00e4hler AK, Kenny PJ, et al. Polygenic overlap between schizophrenia risk and antipsychotic response: a genomic medicine approach. Lancet Psychiatry. 2016;3:350\u20137.","journal-title":"Lancet Psychiatry"},{"key":"360_CR15","doi-asserted-by":"crossref","unstructured":"Li J, Yoshikawa A, Brennan MD, Ramsey TL, Meltzer HY. Genetic predictors of antipsychotic response to lurasidone identified in a genome wide association study and by schizophrenia risk genes. Schizophr Res. 2017.","DOI":"10.1016\/j.schres.2017.04.009"},{"key":"360_CR16","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.schres.2018.04.006","volume":"199","author":"J Li","year":"2018","unstructured":"Li J, Loebel A, Meltzer HY. Identifying the genetic risk factors for treatment response to lurasidone by genome-wide association study: a meta-analysis of samples from three independent clinical trials. Schizophr Res. 2018;199:203\u201313.","journal-title":"Schizophr Res."},{"key":"360_CR17","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1176\/appi.ajp.2011.10060907","volume":"168","author":"HY Meltzer","year":"2011","unstructured":"Meltzer HY, Cucchiaro J, Silva R, Ogasa M, Phillips D, Xu J, et al. Lurasidone in the treatment of schizophrenia: a randomized, double-blind, placebo-and olanzapine-controlled study. Am J Psychiatry. 2011;168:957\u201367.","journal-title":"Am J Psychiatry"},{"key":"360_CR18","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1016\/j.jpsychires.2013.01.020","volume":"47","author":"HA Nasrallah","year":"2013","unstructured":"Nasrallah HA, Silva R, Phillips D, Cucchiaro J, Hsu J, Xu J, et al. Lurasidone for the treatment of acutely psychotic patients with schizophrenia: a 6-week, randomized, placebo-controlled study. J Psychiatr Res. 2013;47:670\u20137.","journal-title":"J Psychiatr Res."},{"key":"360_CR19","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.schres.2013.01.009","volume":"145","author":"A Loebel","year":"2013","unstructured":"Loebel A, Cucchiaro J, Sarma K, Xu L, Hsu C, Kalali AH, et al. Efficacy and safety of lurasidone 80mg\/day and 160mg\/day in the treatment of schizophrenia: a randomized, double-blind, placebo-and active-controlled trial. Schizophr Res. 2013;145:101\u20139.","journal-title":"Schizophr Res."},{"key":"360_CR20","unstructured":"Purcell S, Chang C PLINK 1.9. URL https:\/\/www.cog-genomics.org\/plink2 2015."},{"key":"360_CR21","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1086\/519795","volume":"81","author":"S Purcell","year":"2007","unstructured":"Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet. 2007;81:559\u201375.","journal-title":"Am J Hum Genet."},{"key":"360_CR22","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1038\/ng1847","volume":"38","author":"AL Price","year":"2006","unstructured":"Price AL, Patterson NJ, Plenge RM, Weinblatt ME, Shadick NA, Reich D. Principal components analysis corrects for stratification in genome-wide association studies. Nat Genet. 2006;38:904\u20139.","journal-title":"Nat Genet."},{"key":"360_CR23","doi-asserted-by":"publisher","first-page":"e1004219","DOI":"10.1371\/journal.pcbi.1004219","volume":"11","author":"CA de Leeuw","year":"2015","unstructured":"de Leeuw CA, Mooij JM, Heskes T, Posthuma D. MAGMA: generalized gene-set analysis of GWAS data. PLoS Comput Biol. 2015;11:e1004219.","journal-title":"PLoS Comput Biol."},{"key":"360_CR24","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1093\/aje\/155.5.478","volume":"155","author":"WJ Gauderman","year":"2002","unstructured":"Gauderman WJ. Sample size requirements for association studies of gene-gene interaction. Am J Epidemiol. 2002;155:478\u201384.","journal-title":"Am J Epidemiol."},{"key":"360_CR25","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1038\/s41586-022-04556-w","volume":"604","author":"T Singh","year":"2022","unstructured":"Singh T, Poterba T, Curtis D, Akil H, Al Eissa M, Barchas JD, et al. Rare coding variants in ten genes confer substantial risk for schizophrenia. Nature. 2022;604:509\u201316.","journal-title":"Nature"},{"key":"360_CR26","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.euroneuro.2016.12.001","volume":"27","author":"A Luoni","year":"2017","unstructured":"Luoni A, Richetto J, Longo L, Riva M. Chronic lurasidone treatment normalizes GABAergic marker alterations in the dorsal hippocampus of mice exposed to prenatal immune activation. Eur Neuropsychopharmacol. 2017;27:170\u20139.","journal-title":"Eur Neuropsychopharmacol"},{"key":"360_CR27","doi-asserted-by":"publisher","first-page":"3650","DOI":"10.3390\/ijms19113650","volume":"19","author":"T Numakawa","year":"2018","unstructured":"Numakawa T, Odaka H, Adachi N. Actions of brain-derived neurotrophin factor in the neurogenesis and neuronal function, and its involvement in the pathophysiology of brain diseases. Int J Mol Sci. 2018;19:3650.","journal-title":"Int J Mol Sci."},{"key":"360_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jpsychires.2019.02.007","volume":"112","author":"M Jena","year":"2019","unstructured":"Jena M, Ranjan R, Mishra BR, Mishra A, Nath S, Sahu P, et al. Effect of lurasidone vs olanzapine on neurotrophic biomarkers in unmedicated schizophrenia: a randomized controlled trial. J Psychiatr Res. 2019;112:1\u20136.","journal-title":"J Psychiatr Res."},{"key":"360_CR29","doi-asserted-by":"publisher","first-page":"98","DOI":"10.3389\/fncel.2020.00098","volume":"14","author":"Q Delmotte","year":"2020","unstructured":"Delmotte Q, Diabira D, Belaidouni Y, Hamze M, Kochmann M, Montheil A, et al. Sonic hedgehog signaling agonist (SAG) triggers BDNF secretion and promotes the maturation of GABAergic networks in the postnatal Rat hippocampus. Front Cell Neurosci. 2020;14:98.","journal-title":"Front Cell Neurosci."},{"key":"360_CR30","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/0896-6273(95)90062-4","volume":"15","author":"M Hynes","year":"1995","unstructured":"Hynes M, Porter JA, Chiang C, Chang D, Tessier-Lavigne M, Beachy PA, et al. Induction of midbrain dopaminergic neurons by Sonic hedgehog. Neuron. 1995;15:35\u201344.","journal-title":"Neuron"},{"key":"360_CR31","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1242\/dev.058917","volume":"138","author":"Y Jeong","year":"2011","unstructured":"Jeong Y, Dolson DK, Waclaw RR, Matise MP, Sussel L, Campbell K, et al. Spatial and temporal requirements for sonic hedgehog in the regulation of thalamic interneuron identity. Development. 2011;138:531\u201341.","journal-title":"Development"},{"key":"360_CR32","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/S0166-2236(02)02062-3","volume":"25","author":"E Mart\u0131\u0301","year":"2002","unstructured":"Mart\u0131\u0301 E, Bovolenta P. Sonic hedgehog in CNS development: one signal, multiple outputs. Trends Neurosci. 2002;25:89\u201396.","journal-title":"Trends Neurosci."},{"key":"360_CR33","doi-asserted-by":"publisher","first-page":"eaao5749","DOI":"10.1126\/scisignal.aao5749","volume":"11","author":"GV Pusapati","year":"2018","unstructured":"Pusapati GV, Kong JH, Patel BB, Gouti M, Sagner A, Sircar R, et al. G protein\u2013coupled receptors control the sensitivity of cells to the morphogen Sonic Hedgehog. Sci Signal. 2018;11:eaao5749.","journal-title":"Sci Signal."},{"key":"360_CR34","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1124\/mol.110.066431","volume":"78","author":"M Lauth","year":"2010","unstructured":"Lauth M, Rohnalter V, Bergstr\u00f6m \u00c5, Kooshesh M, Svenningsson P, Toftg\u00e5rd R. Antipsychotic drugs regulate hedgehog signaling by modulation of 7-dehydrocholesterol reductase levels. Mol Pharmacol. 2010;78:486\u201396.","journal-title":"Mol Pharmacol"},{"key":"360_CR35","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.neuron.2011.12.012","volume":"73","author":"SG Brickley","year":"2012","unstructured":"Brickley SG, Mody I. Extrasynaptic GABA A receptors: their function in the CNS and implications for disease. Neuron. 2012;73:23\u201334.","journal-title":"Neuron"},{"key":"360_CR36","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1038\/nrd3502","volume":"10","author":"U Rudolph","year":"2011","unstructured":"Rudolph U, Knoflach F. Beyond classical benzodiazepines: novel therapeutic potential of GABA A receptor subtypes. Nat Rev Drug Discov. 2011;10:685.","journal-title":"Nat Rev Drug Discov"},{"key":"360_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1471-4159.2007.04454.x","volume":"102","author":"H M\u00f6hler","year":"2007","unstructured":"M\u00f6hler H. Molecular regulation of cognitive functions and developmental plasticity: impact of GABAA receptors. J Neurochem. 2007;102:1\u201312.","journal-title":"J Neurochem"},{"key":"360_CR38","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.neuron.2011.12.012","volume":"73","author":"SG Brickley","year":"2012","unstructured":"Brickley SG, Mody I. Extrasynaptic GABAA receptors: their function in the CNS and implications for disease. Neuron. 2012;73:23\u201334.","journal-title":"Neuron"},{"key":"360_CR39","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1038\/sj.mp.4001556","volume":"10","author":"S Miyamoto","year":"2005","unstructured":"Miyamoto S, Duncan G, Marx C, Lieberman J. Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mol Psychiatry. 2005;10:79.","journal-title":"Mol Psychiatry"},{"key":"360_CR40","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1146\/annurev-pharmtox-011613-135947","volume":"54","author":"U Rudolph","year":"2014","unstructured":"Rudolph U, M\u00f6hler H. GABAA receptor subtypes: therapeutic potential in Down syndrome, affective disorders, schizophrenia, and autism. Annu Rev Pharmacol Toxicol. 2014;54:483.","journal-title":"Annu Rev Pharmacol Toxicol."},{"key":"360_CR41","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.2174\/156802611795371314","volume":"11","author":"J Atack","year":"2011","unstructured":"Atack J. GABAA receptor subtype-selective modulators. II. \u03b15-selective inverse agonists for cognition enhancement. Curr Top Medicinal Chem. 2011;11:1203\u201314.","journal-title":"Curr Top Medicinal Chem"},{"key":"360_CR42","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1093\/cercor\/12.8.831","volume":"12","author":"J Soria","year":"2002","unstructured":"Soria J, Valdeolmillos M. Receptor-activated calcium signals in tangentially migrating cortical cells. Cereb Cortex. 2002;12:831\u20139.","journal-title":"Cereb Cortex"},{"key":"360_CR43","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1111\/j.1460-9568.2006.04630.x","volume":"23","author":"C M\u00e9tin","year":"2006","unstructured":"M\u00e9tin C, Baudoin JP, Raki\u0107 S, Parnavelas JG. Cell and molecular mechanisms involved in the migration of cortical interneurons. Eur J Neurosci. 2006;23:894\u2013900.","journal-title":"Eur J Neurosci"},{"key":"360_CR44","doi-asserted-by":"publisher","first-page":"3813","DOI":"10.1523\/JNEUROSCI.5124-06.2007","volume":"27","author":"JE Crandall","year":"2007","unstructured":"Crandall JE, McCarthy DM, Araki KY, Sims JR, Ren J-Q, Bhide PG. Dopamine receptor activation modulates GABA neuron migration from the basal forebrain to the cerebral cortex. J Neurosci. 2007;27:3813\u201322.","journal-title":"J Neurosci."},{"key":"360_CR45","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1111\/j.1460-9568.2011.07867.x","volume":"34","author":"JB Manent","year":"2011","unstructured":"Manent JB, Beguin S, Ganay T, Represa A. Cell\u2010autonomous and cell\u2010to\u2010cell signalling events in normal and altered neuronal migration. Eur J Neurosci. 2011;34:1595\u2013608.","journal-title":"Eur J Neurosci"},{"key":"360_CR46","doi-asserted-by":"publisher","first-page":"115","DOI":"10.3389\/fnins.2012.00115","volume":"6","author":"O Kohannim","year":"2012","unstructured":"Kohannim O, Hibar DP, Stein JL, Jahanshad N, Hua X, Rajagopalan P, et al. Discovery and replication of gene influences on brain structure using LASSO regression. Front Neurosci. 2012;6:115.","journal-title":"Front Neurosci."},{"key":"360_CR47","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1093\/schbul\/sbs118","volume":"39","author":"SV Haijma","year":"2013","unstructured":"Haijma SV, Van Haren N, Cahn W, Koolschijn PCM, Hulshoff Pol HE, Kahn RS. Brain volumes in schizophrenia: a meta-analysis in over 18,000 subjects. Schizophr Bull. 2013;39:1129\u201338.","journal-title":"Schizophr Bull."},{"key":"360_CR48","doi-asserted-by":"crossref","unstructured":"Xu B, Woodroffe A, Rodriguez-Murillo L, Roos JL, van Rensburg EJ, Abecasis GR, et al. Elucidating the genetic architecture of familial schizophrenia using rare copy number variant and linkage scans. Proc Natl Acad Sci. 2009;106:16746\u201351.","DOI":"10.1073\/pnas.0908584106"},{"key":"360_CR49","doi-asserted-by":"publisher","first-page":"12974","DOI":"10.1074\/jbc.M008089200","volume":"276","author":"C B\u00e9camel","year":"2001","unstructured":"B\u00e9camel C, Figge A, Poliak S, Dumuis A, Peles E, Bockaert J, et al. Interaction of serotonin 5-hydroxytryptamine type 2C receptors with PDZ10 of the multi-PDZ domain protein MUPP1. J Biol Chem. 2001;276:12974\u201382.","journal-title":"J Biol Chem"},{"key":"360_CR50","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1038\/nrn1517","volume":"5","author":"E Kim","year":"2004","unstructured":"Kim E, Sheng M. PDZ domain proteins of synapses. Nat Rev Neurosci. 2004;5:771\u201381.","journal-title":"Nat Rev Neurosci"},{"key":"360_CR51","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1002\/jnr.22688","volume":"89","author":"S Harashima","year":"2011","unstructured":"Harashima S, Wang Y, Horiuchi T, Seino Y, Inagaki N. Purkinje cell protein 4 positively regulates neurite outgrowth and neurotransmitter release. J Neurosci Res. 2011;89:1519\u201330.","journal-title":"J Neurosci Res"},{"key":"360_CR52","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1111\/j.1471-4159.2011.07565.x","volume":"120","author":"S Purkayastha","year":"2012","unstructured":"Purkayastha S, Ford J, Kanjilal B, Diallo S, Del Rosario Inigo J, Neuwirth L, et al. Clozapine functions through the prefrontal cortex serotonin 1A receptor to heighten neuronal activity via calmodulin kinase II\u2013NMDA receptor interactions. J Neurochem. 2012;120:396\u2013407.","journal-title":"J Neurochem"},{"key":"360_CR53","doi-asserted-by":"publisher","first-page":"3001","DOI":"10.1007\/s00429-019-01945-2","volume":"224","author":"ET Rolls","year":"2019","unstructured":"Rolls ET. The cingulate cortex and limbic systems for emotion, action, and memory. Brain Struct Funct. 2019;224:3001\u201318.","journal-title":"Brain Struct Funct."},{"key":"360_CR54","doi-asserted-by":"crossref","unstructured":"Tarcijonas G, Sarpal DK. Neuroimaging markers of antipsychotic treatment response in schizophrenia: an overview of magnetic resonance imaging studies. Neurobiol Dis. 2018;131:1\u201315.","DOI":"10.1016\/j.nbd.2018.06.021"},{"key":"360_CR55","doi-asserted-by":"publisher","first-page":"2675","DOI":"10.1038\/npp.2009.94","volume":"34","author":"AC Lahti","year":"2009","unstructured":"Lahti AC, Weiler MA, Holcomb HH, Tamminga CA, Cropsey KL. Modulation of limbic circuitry predicts treatment response to antipsychotic medication: a functional imaging study in schizophrenia. Neuropsychopharmacology. 2009;34:2675.","journal-title":"Neuropsychopharmacology"},{"key":"360_CR56","doi-asserted-by":"crossref","unstructured":"Fan L, Liang L, Wang Y, Ma X, Yuan L, Ouyang L, et al. Glutamatergic basis of antipsychotic response in first-episode psychosis: a dual voxel study of the anterior cingulate cortex. Neuropsychopharmacology. 2023;49:1\u20139.","DOI":"10.21203\/rs.3.rs-3054860\/v1"},{"key":"360_CR57","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1038\/s41386-022-01508-w","volume":"48","author":"A Egerton","year":"2023","unstructured":"Egerton A, Griffiths K, Casetta C, Deakin B, Drake R, Howes OD, et al. Anterior cingulate glutamate metabolites as a predictor of antipsychotic response in first episode psychosis: data from the STRATA collaboration. Neuropsychopharmacology. 2023;48:567\u201375.","journal-title":"Neuropsychopharmacology"},{"key":"360_CR58","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1111\/cns.12986","volume":"24","author":"HY Meltzer","year":"2018","unstructured":"Meltzer HY, Sim MY, Anderson A, Cannistraci C, Jayathilake K, Share DB, et al. A within\u2010subject consideration of the psychotic spectrum disorder concept in a patient in remission associated with cortical gray matter recovery. CNS Neurosci Ther. 2018;24:641\u201351.","journal-title":"CNS Neurosci Ther"},{"key":"360_CR59","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1038\/nm.4218","volume":"22","author":"S Yun","year":"2016","unstructured":"Yun S, Reynolds RP, Masiulis I, Eisch AJ. Re-evaluating the link between neuropsychiatric disorders and dysregulated adult neurogenesis. Nat. Med. 2016;22:1239\u201347.","journal-title":"Nat. Med."},{"key":"360_CR60","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1093\/schbul\/sbq134","volume":"37","author":"D Inta","year":"2011","unstructured":"Inta D, Meyer-Lindenberg A, Gass P. Alterations in postnatal neurogenesis and dopamine dysregulation in schizophrenia: a hypothesis. Schizophr Bull. 2011;37:674\u201380.","journal-title":"Schizophr Bull."},{"key":"360_CR61","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1038\/ng1706","volume":"38","author":"AD Skol","year":"2006","unstructured":"Skol AD, Scott LJ, Abecasis GR, Boehnke M. Joint analysis is more efficient than replication-based analysis for two-stage genome-wide association studies. Nat Genet. 2006;38:209\u201313.","journal-title":"Nat Genet"},{"key":"360_CR62","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/S2215-0366(18)30064-6","volume":"5","author":"M Ikeda","year":"2018","unstructured":"Ikeda M, Mushiroda T. The genetics of antipsychotic response in schizophrenia. Lancet Psychiatry. 2018;5:291\u20132.","journal-title":"Lancet Psychiatry"}],"container-title":["The Pharmacogenomics Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41397-024-00360-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41397-024-00360-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41397-024-00360-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T04:02:39Z","timestamp":1745380959000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41397-024-00360-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,20]]},"references-count":62,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["360"],"URL":"https:\/\/doi.org\/10.1038\/s41397-024-00360-z","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3372085\/v1","asserted-by":"object"}]},"ISSN":["1470-269X","1473-1150"],"issn-type":[{"value":"1470-269X","type":"print"},{"value":"1473-1150","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,20]]},"assertion":[{"value":"20 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"AY, JL and NAR have no conflict of interest. HYM is a stockholder in ACADIA and receives additional grant support from Sunovion and Sumitomo Dainippon Pharma for other studies. HYM also receives grant support from Auspex, Eli Lilly, Janssen, Lundbeck, Mag T, and Allergan. This research was also supported by donations from the Weisman Family, Mr. Michael Burke, and Mr. Michael Shmerling.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"3"}}